PMID- 34699021
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211112
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 12
DP  - 2021 Dec
TI  - Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A 
      Critical Review.
PG  - 3037-3054
LID - 10.1007/s13300-021-01170-3 [doi]
AB  - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus 
      disease 2019 (COVID-19). The latter is a pandemic that has the potential of 
      developing into a severe illness manifesting as systemic inflammatory response 
      syndrome, acute respiratory distress syndrome, multi-organ involvement and shock. 
      In addition, advanced age and male sex and certain underlying health conditions, 
      like type 2 diabetes mellitus (T2DM), predispose to a higher risk of greater 
      COVID-19 severity and mortality. This calls for an urgent identification of 
      antidiabetic agents associated with more favourable COVID-19 outcomes among 
      patients with T2DM, as well as recognition of their potential underlying 
      mechanisms. It is crucial that individuals with T2DM be kept under very stringent 
      glycaemic control in order to avoid developing various cardiovascular, renal and 
      metabolic complications associated with more severe forms of COVID-19 that lead 
      to increased mortality. The use of novel antidiabetic agents dipeptidyl 
      peptidase 4 inhibitors (DPP4i), sodium-glucose co-transporter 2 inhibitors 
      (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RAs) in subjects 
      with T2DM may have beneficial effects on COVID-19 outcomes. However, relevant 
      studies either show inconsistent results (DPP4i) or are still too few (SGLT2i and 
      GLP-1RAs). Further research is therefore needed to assess the impact of these 
      agents on COVID-19 outcomes.
CI  - (c) 2021. The Author(s).
FAU - Popovic, Djordje S
AU  - Popovic DS
AD  - Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of 
      Vojvodina, Novi Sad, Serbia.
AD  - Medical Faculty, University of Novi Sad, Novi Sad, Serbia.
FAU - Papanas, Nikolaos
AU  - Papanas N
AD  - Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, 
      Democritus University of Thrace, University Hospital of Alexandroupolis, 
      Alexandroupoli, Greece.
FAU - Pantea Stoian, Anca
AU  - Pantea Stoian A
AD  - Faculty of Medicine, Department of Diabetes, Nutrition and Metabolic Diseases, 
      Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 
      ancastoian@yahoo.com.
FAU - Rizvi, Ali A
AU  - Rizvi AA
AD  - Division of Endocrinology, Metabolism, and Lipids, Emory University School of 
      Medicine, Atlanta, GA, USA.
AD  - Division of Endocrinology, Diabetes and Metabolism, University of South Carolina 
      School of Medicine, Columbia, SC, USA.
FAU - Janez, Andrej
AU  - Janez A
AD  - Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical 
      Centre Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, 
      Slovenia.
FAU - Rizzo, Manfredi
AU  - Rizzo M
AD  - Faculty of Medicine, Department of Diabetes, Nutrition and Metabolic Diseases, 
      Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
AD  - Division of Endocrinology, Diabetes and Metabolism, University of South Carolina 
      School of Medicine, Columbia, SC, USA.
AD  - Department of Health Promotion Sciences Maternal and Infantile Care, Internal 
      Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211026
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC8546380
OTO - NOTNLM
OT  - COVID-19
OT  - Dipeptidyl peptidase 4 inhibitors
OT  - Glucagon-like peptide 1 receptor agonists
OT  - Sodium-glucose co-transporter 2 inhibitors
OT  - Type 2 diabetes
EDAT- 2021/10/27 06:00
MHDA- 2021/10/27 06:01
PMCR- 2021/10/26
CRDT- 2021/10/26 12:35
PHST- 2021/08/09 00:00 [received]
PHST- 2021/10/05 00:00 [accepted]
PHST- 2021/10/27 06:00 [pubmed]
PHST- 2021/10/27 06:01 [medline]
PHST- 2021/10/26 12:35 [entrez]
PHST- 2021/10/26 00:00 [pmc-release]
AID - 10.1007/s13300-021-01170-3 [pii]
AID - 1170 [pii]
AID - 10.1007/s13300-021-01170-3 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Dec;12(12):3037-3054. doi: 10.1007/s13300-021-01170-3. Epub 
      2021 Oct 26.